TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis - PubMed (original) (raw)
. 2011 Jul 12;20(1):25-38.
doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.
Lucile Couronné, Véronique Della Valle, Cécile K Lopez, Isabelle Plo, Orianne Wagner-Ballon, Marcio Do Cruzeiro, Francois Delhommeau, Bertrand Arnulf, Marc-Henri Stern, Lucy Godley, Paule Opolon, Hervé Tilly, Eric Solary, Yannis Duffourd, Philippe Dessen, Hélène Merle-Beral, Florence Nguyen-Khac, Michaëla Fontenay, William Vainchenker, Christian Bastard, Thomas Mercher, Olivier A Bernard
Affiliations
- PMID: 21723201
- DOI: 10.1016/j.ccr.2011.06.003
Free article
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis
Cyril Quivoron et al. Cancer Cell. 2011.
Free article
Abstract
Loss-of-function mutations affecting one or both copies of the Ten-Eleven-translocation (TET)2 gene have been described in various human myeloid malignancies. We report that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a cell-autonomous manner, endows the cells with competitive advantage, and eventually leads to the development of malignancies. We subsequently observed TET2 mutations in human lymphoid disorders. TET2 mutations could be detected in immature progenitors endowed with myeloid colony-forming potential. Our results show that the mutations present in lymphoid tumor cells may occur at both early and later steps of lymphoid development and indicate that impairment of TET2 function or/and expression predisposes to the development of hematological malignancies.
Copyright © 2011 Elsevier Inc. All rights reserved.
Comment in
- The role of TET2 in hematologic neoplasms.
Holmfeldt L, Mullighan CG. Holmfeldt L, et al. Cancer Cell. 2011 Jul 12;20(1):1-2. doi: 10.1016/j.ccr.2011.06.025. Cancer Cell. 2011. PMID: 21741591
Similar articles
- Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick A, Godley LA, Aifantis I, Levine RL. Moran-Crusio K, et al. Cancer Cell. 2011 Jul 12;20(1):11-24. doi: 10.1016/j.ccr.2011.06.001. Epub 2011 Jun 30. Cancer Cell. 2011. PMID: 21723200 Free PMC article. - The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. Solary E, et al. Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220273 Review. - Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.
Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB, Rao A. Ko M, et al. Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14566-71. doi: 10.1073/pnas.1112317108. Epub 2011 Aug 22. Proc Natl Acad Sci U S A. 2011. PMID: 21873190 Free PMC article. - Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells.
Kunimoto H, McKenney AS, Meydan C, Shank K, Nazir A, Rapaport F, Durham B, Garrett-Bakelman FE, Pronier E, Shih AH, Melnick A, Chaudhuri J, Levine RL. Kunimoto H, et al. Blood. 2017 Mar 30;129(13):1779-1790. doi: 10.1182/blood-2016-06-721977. Epub 2017 Jan 11. Blood. 2017. PMID: 28077417 Free PMC article. - TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Nakajima H, Kunimoto H. Nakajima H, et al. Cancer Sci. 2014 Sep;105(9):1093-9. doi: 10.1111/cas.12484. Epub 2014 Sep 3. Cancer Sci. 2014. PMID: 25040794 Free PMC article. Review.
Cited by
- TET proteins: on the frenetic hunt for new cytosine modifications.
Delatte B, Fuks F. Delatte B, et al. Brief Funct Genomics. 2013 May;12(3):191-204. doi: 10.1093/bfgp/elt010. Epub 2013 Apr 26. Brief Funct Genomics. 2013. PMID: 23625996 Free PMC article. Review. - TET2: A cornerstone in normal and malignant hematopoiesis.
Kunimoto H, Nakajima H. Kunimoto H, et al. Cancer Sci. 2021 Jan;112(1):31-40. doi: 10.1111/cas.14688. Epub 2020 Nov 18. Cancer Sci. 2021. PMID: 33048426 Free PMC article. Review. - Nutritional Status Impacts Epigenetic Regulation in Early Embryo Development: A Scoping Review.
Cai S, Quan S, Yang G, Chen M, Ye Q, Wang G, Yu H, Wang Y, Qiao S, Zeng X. Cai S, et al. Adv Nutr. 2021 Oct 1;12(5):1877-1892. doi: 10.1093/advances/nmab038. Adv Nutr. 2021. PMID: 33873200 Free PMC article. Review. - Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis.
Wallace L, Obeng EA. Wallace L, et al. Front Mol Biosci. 2023 Oct 31;10:1273046. doi: 10.3389/fmolb.2023.1273046. eCollection 2023. Front Mol Biosci. 2023. PMID: 38028538 Free PMC article. Review. - IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, Chan LC, Chan WC, Gaulard P, Mak TW. Cairns RA, et al. Blood. 2012 Feb 23;119(8):1901-3. doi: 10.1182/blood-2011-11-391748. Epub 2012 Jan 3. Blood. 2012. PMID: 22215888 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases